The Food and Drug Administration has given the go-ahead to oral risedronate sodium (Actonel) for the treatment of idiopathic osteoporosis in men following the conclusion of a study that found that the drug had bone mineral density benefits equivalent to those seen in postmenopausal women.
PREVIEW